Comparison of DIPSS and MYSEC-PM for prediction of outcome in post-PV and ET myelofibrosis after allogeneic stem-cell transplantation

In the last decade, three clinical-derived prognostic models have been developed in patients with primary myelofibrosis [1 –3]. Prognostication in myeloproliferative neoplasms, however, is moving towards integrated clinical-molecular models [4,5]. Therefore, more recently, another prognostic system has been developed and validated by the MYSEC project (MYelofibrosis SECondary to PV and ET) specifically for myelofibros is evolved from polycythemia vera (post-PV MF) and essential thrombocythemia (post-ET MF) [6,7].

Source: Biology of Blood and Marrow Transplantation - March 27, 2019 Category: Hematology Authors: Nico Gagelmann, Diderik-Jan Eikema, Liesbeth C de Wreede, Linda Koster, Christine Wolschke, Renate Arnold, Lothar Kanz, Grant McQuaker, Tony Marchand, Gerard Soci é, Jean Henri Bourhis, Mohamad Mohty, Jan J Cornelissen, Patrice Chevallier, Paolo Bernasco Source Type: research